AGMB-447
Asset
Inhaled small molecule ALK5 (TGF-beta type I receptor) inhibitor targeting lung fibrosis.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- TGFBR1
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Idiopathic pulmonary fibrosis
Phase 2, Not yet recruiting, NCT07862634, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors11
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.